

# Dermatologie et Voyages

Eric Caumes. Université Pierre et Marie Curie, Paris


Dept infectious and tropical diseases; Hop Pitié-Salpêtrière.



# Potential links of Interests

- In the past 2 years, I (or my department) have received honoraria from **BMS**, **Baxter**, **Galen** and **Codexial** for lectures on STDs and participation in advisory boards (TBE vaccine, KS, permethrin).
- I am the Editor in Chief of the **Journal of Travel Medicine** (IF = 1.47) (submission wellcome)

# Dermatoses in 8.227 ill travelers (19%), GeoSentinel, 2007-2011



Leder K et al. Ann Intern Med 2013; 158: 456-468

# **The top nine travel associated dermatoses\* in 4594 pts, 1997-2006, WW travellers (GeoS)**

|                                    |                    |
|------------------------------------|--------------------|
| <b>Cutaneous larva migrans</b>     | <b>: 465 (10%)</b> |
| <b>Insect bites</b>                | <b>: 388 (8%)</b>  |
| <b>Abcess (pyoderma)</b>           | <b>: 366 (7%)</b>  |
| <b>Surinfected insect bites</b>    | <b>: 324 (7%)</b>  |
| <b>Cutaneous allergy</b>           | <b>: 263 (5%)</b>  |
| <b>Rash of undetermined origin</b> | <b>: 262 (5%)</b>  |
| <b>Bite by animals</b>             | <b>: 203 (4%)</b>  |
| <b>Superficial mycose</b>          | <b>: 190 (4%)</b>  |
| <b>Dengue</b>                      | <b>: 159 (3%)</b>  |

\* 24% tropical;

**SSTI :**  
**690**  
**(15%)**

Lederman E et al. Int J Inf Dis 2008,  
i:10.1016/i.infdis.2007.12.008

# The top nine travel associated dermatoses\* in 114 pts, 2000s, tourists, migrants, expat


|                                |             |
|--------------------------------|-------------|
| <b>Infectious cellulitis</b>   | : 21 (14%)  |
| <b>Scabies</b>                 | : 17 (11%)  |
| <b>PUO</b>                     | : 15 (10 %) |
| <b>Pyoderma</b>                | : 14 (9%)   |
| <b>Myiasis</b>                 | : 12 (8%)   |
| <b>Tinea</b>                   | : 10 (6%)   |
| <b>Filariasis</b>              | : 9 (6%)    |
| <b>Cutaneous Larva migrans</b> | : 8 (5%)    |
| <b>Urticaria</b>               | : 8 (5%)    |

**SSTI : 35  
(23%)**

\* 76 % of 149 dermatoses (34% tropical)

Ansart S et al. Am J Trop Med Hyg 2007; 76 : 184-186

# Top diagnoses in 1586 travellers /Brazil Geosentinel – 7/1997-05/2013






# **70 patients with creeping dermatitis, 2008-2012**

| <b>Disease</b>   | <b>Number of cases (%)</b>               |
|--|--|
| <b>HrCLM including Hookworm folliculitis</b>           | <b>66 (94%) including<br/>7/66 (11%)</b> |
| Gnathostomiasis  | 2 (3%)                                   |
| Loiasis  | 1 (1.5%)                                 |
| Creeping (dog) hair                                    | 1 (1.5%)                                 |
| Migratory myiasis,<br>dirofilariasis, larva<br>currens | 0  |




# Confocal microscopic identification of hookworm larvae in HrCLM (Purdy KS et al. Lancet 2011; 377: 1948)

(A) Serpiginous eruption of plantar aspect of right foot. (B) Reflectance confocal microscope imaging showing highly refractile oval larva (arrow). (C) Histological examination of punch biopsy extraction showing richly eosinophilic intact hookworm larva (arrow) within the epidermis.



# Identification of *Ancylostoma braziliense* in HrCLM



Le Joncour A et al. Am J Trop Med Hyg 2012; 86:843-5



**hookworm larva recovered  
from a skin scraping of folliculitis  
Lesion (optical micro, x40)**

**Living hookworm larva recovered  
from a skin scraping of folliculitis  
Lesion (optical micro, x10)**



**Le Joncour A et al. Am J Trop Med Hyg 2012;**

# HrCLM : efficacy of ivermectin varies with the clinical presentation.

- 62 travellers (35 F, 27 M, 35 y) with HrCLM
- Tt : 200 µg/kg ivermectin, single dose.
- All pts had creeping dermatitis and 6 patients (10%) also had hookworm folliculitis (HF).
- Overall CR = 59/62 pts (95%). **CR = 98% in the 56 pts presenting with only creeping dermatitis and 66% in the 6 pts with HF (p < 0.01)**

Vanhaecke C et al. J Eur Acad Dermatol Venereol 2013

# HrCLM in Lome, Togo: clinique et traitement par albendazole

- 163/22.628 pts (0.7%) presented with HrCLM
  - 15 +/- 14 year old, H/F=1.8
  - Time after appearance = 4 +/- 3 weeks
  - Pruritus : 97%
  - Buttocks (38%), lower limbs (35%),...
  - Superinfection : 6 (3.8%)
- Tt: Albendazole 200 - 400 mg/d x 3 days. 77 pts evaluable for Cure (Wk 2). **CR = 69/77 (89%).**

Saka B et al. Ann Dermatol Venereol 2012; 139: 564-567

# Albendazole in HrCLM

| Ref           | N= | Dosage            | Cure rate |
|---------------|----|-------------------|-----------|
| Coulaud, 1987 | 18 | 400 mg/d x 5 d    | 100%      |
| Veraldi, 2011 | 78 | 400 mg/d x 7d     | 100%      |
| Kaba, 2012    | 77 | 200-400 mg/d x 3d | 89%       |

| Ref            | N= | Dosage         | Cure rate |
|----------------|----|----------------|-----------|
| Jones, 1990    | 2  | 800 mg/d x 3 d | 100%      |
| Williams, 1989 | 4  | 800 mg/d x 3 d | 100%      |

Tokyo, Japan



Tokyo



# The « Leisman » recommandations: a species & severity based approach

- 1 – « Primum non nocere » approach  
(simple wound care) for minor (self healing) LCL (Lm, Lt, Li, Lae/Lmex)
- 2 – Local (IL AM/paromomycin ointment) for moderate LCL
- 3 – Systemic (AM at last) for extensive disease  $\pm$  LCL (Lb, Lp)

# **Imported LCL, France, 2006-2011**

## **70 pts: species prediction by experts**

70/135 (52%)  
species identified  
by PCR

OW

NW

Correct  
identification by  
clinical expert

96%

74%

Correlation K      0.93 (0.9-1.00)      0.59 (0.4-0.8)

# How determining the culprit species in LCL ?

- Clinical presentation may give an orientation but lacks of specificity – Tunisia (Aoun K, 2013); Guatemala (Herwaldt, 1992)
- Place of acquisition is reliable for OW species if: a) geographic distribution is well known, b) no species overlap, c) single place (Morizot G, 2013)
  - <https://www.parasitologie.univ-montp1.fr/cnrl2.htm>
  - <https://www.whp.int/topics/leishmaniasis/fr>

Buffet P. Ann Dermatol Venereol 2012; 139: 515-517.  
Morizot G et al. Clin Infect Dis 2013


# **Imported LCL, France, 2006-2011 treatment outcome in 109 pts**

| Tt option    | Wound care | CryoTt/IL  | Syst Tt    |
|--------------|------------|------------|------------|
| N=           | 25         | 47         | 37         |
| L.major      | 80%        | 60%        | 35%        |
| L.guyan      | 8%         | 0          | 25%        |
| <b>Cured</b> | <b>92%</b> | <b>79%</b> | <b>60%</b> |
| AE           | 0          | 0          | 32%        |

# Local treatment for LCL

- ....and so there is obvious selection bias....However...the results remain valuable as most centers will have treated these patients systemically with higher cost and risk of AE
- Existing local treatments (IL injections of AM, cryotherapy, topical paromomycine, and thermotherapy) are worthy of further evaluation

# LeishMan Recommendations for Tt of LCL and ML in Travelers.




Procedures for superficial cryotherapy and/or intralesional injection of antimony. The lesion is first swabbed with antiseptics several mns before starting the procedure.

(A) Cryotherapy: cryotherapy with liquid nitrogen is then applied on the lesion (A1) and immediate borders (A2)—ideally with a sprayer—3- to 5-second blanching is obtained.

(B and C) Intralesional injection: Antimony as formulated for parenteral administration by the manufacturer (B) is injected into the lesion (C1) and should induce blanching of the borders (C2, arrows), until the lesion is entirely swollen (before procedure C3, end of procedure C4). The procedure is usually repeated 2 to 10 times at 2 to 8 day intervals.

# Intralesional meglumine antimoniate, cryotherapy and combination



Procedure for  
intralesional treatment  
with pentavalent  
Antimony : advance  
the needle while  
injecting under  
pressure in the  
dermis, covering the  
whole lesion including  
the center.

Salmanpour R, et al. Int J  
Dermatol 2006; 45:1115-6.

# **Topical paromomycin +/- gentamycin vs placebo for LCL in Tunisia (*L.major*)**

| Tt for 20 days      | Paro 15%   | Paro 15%   | Vehicule   |
|---------------------|------------|------------|------------|
| mITT pop            |            | Genta 0.5% |            |
| N =                 | 125        | 125        | 125        |
| <b>Cure rate IL</b> | <b>82%</b> | <b>81%</b> | <b>58%</b> |
| <b>Superinfect°</b> | <b>2%</b>  | <b>0%</b>  | <b>10%</b> |
| <b>AE vesicles</b>  | <b>26%</b> | <b>25%</b> | <b>7%</b>  |

**Differences between Tt groups : P < 0.001 vs vehicule**

Ben Salah A et al. N Engl J Med 2013; 368: 524-532



# Etiologies Exanthème fébrile chez 62 voyageurs au retour

|                 |  |
|-----------------|--|
| <b>Virus</b>    | <b>Chikungunya</b> (35%), <b>dengue</b> (26%), EBV (5%), HIV (3%), CMV (2%), Rougeole, Rubeole et varicelle (2%) |
| <b>Bacteria</b> | <b>Fièvre Africaine à tiques</b> (10%), Toxic Strep syndrome (2%)  |
| <b>Parasite</b> | Toxoplasmose, bilharziose aigue (2%)   |
| <b>ADR</b>      | Nevirapine (traitement prophylactique post exposition en Afrique (2%)  |
| <b>Unknown</b>  | 8%   |

Hochedez P et al. Am J Trop Med Hyg 2008; 78:710-713

# Dengue vs Chikungunya

| <b>Variable</b>       | <b>Chikungunya</b> | <b>Dengue</b> | <b>P =</b> |
|-----------------------|--------------------|---------------|------------|
|                       | <b>N = 22</b>      | <b>N = 16</b> |            |
| <b>Arthralgies</b>    | 100%               | 0%            | <0.001     |
| Prurit                | 48%                | 31%           | NS         |
| <b>Neutropénie</b>    | 10%                | 81%           | <0.001     |
| <b>Thrombopenie</b>   | 35%                | 88%           | 0.002      |
| Cytolyse<br>hépatique | 65%                | 88%           | NS         |

Hochedez P et al. Am J Trop Med Hyg 2008; 78:710-713

# Zika virus in Thailand and Polynesia

50 years old German, Nov 2013

12 days after returning from Thailand

Dengue like sd

Serologically confirmed

Tappe D. Eurosurveillance  
2014;19:20685

---

2 Japanese, 20 and 30 years

Dec.2013-janv.2014

6-10 days in French Polynesia

1 day after return in both

Dengue like sd with Rash

PCR confirmed

Kutsuma S. Eurosurveillance  
2014;19:20685

# **Sexual transmission of Zika virus**

Pts 1 and 2; Senegal, aug 2008 ;


become ill 6-9 days > return

Pt 3 (wife of pt 1) became ill 9 days after pt 1 return from Senegal and 4 days after felt ill (with hematospermia and lips erosions)

→ sexual transmission (day 1 after return) is the only possible way of transmission

**FIGURE 4**

Weekly incidence of the estimated suspected cases of chikungunya by the sentinel network in Guadeloupe, Martinique, Saint Barthélemy and Saint Martin, 1 December 2013–26 January 2014



The period 1 December 2013–26 January 2014 corresponds to the weeks 48 2013–4 2014.

# **Chikungunya in Carribbeans**

- 2013 (wk 48): Saint Martin
- 2013 (wk 52): Saint Barthelemy
- 2013 (wk 54): Martinique (French West indies) and British Virgin islands
- 2014 (wk 1): Guadeloupe


**Van Bortel W et al. Euro Surveill 2014; 19 (13): 20759  
Editorial. Lancet 2014; 383: 488  
Leparc-Goffart I. Lancet 2014; 383: 514-515  
Cassadou S. Euro Surveill 2014; 19 (13): 20752**

# **Chikungunya outbreak - The Caribbean, 2013-2014**


- **Anguilla**, 33 confirmed cases;
- **Antigua and Barbuda**, 4 cases;
- **Aruba**, 1 imported case originating from Saint Maarten;
- **Dominica**, 1 817 suspected cases and 122 confirmed cases;
- **Dominican Republic**, 8 017 suspected and 17 confirmed cases;
- **Guadeloupe**, 18 000 suspected and 1 328 cases, one death;
- **Haiti**, 632 confirmed cases;
- **Martinique**, 26 670 suspected and 1 515 cases, 9 deaths;
- **Saint Barthélemy**, 510 suspected and 135 cases;
- **Saint Lucia**, 5 confirmed cases;
- **Saint Martin (FR)**, 3 280 suspected and 793 cases, 3 deaths;
- **Saint Vincent**, 110 suspected cases and 57 cases;
- .....
- **French Guiana**, 176 cases 70% of which autochthonous;

**FIGURE 3**

Local chikungunya transmission and imported cases in the islands of the Caribbean region and in French Guiana, 1 December 2013–23 February 2014




# Brazil World cup and Olympics cities Malaria and YF risk areas




Wilson M et GeoSentinel.  
Clin Infect Dis  
2014; 58: 1347-1356

# Dengue, Brazil World cup and Olympics





# Recommandations de Bonne Pratique



## ■ Protection personnelle antivectorielle à l'attention des voyageurs, des expatriés, des résidants et des nomades



PPAV group (including G. Duvallet, L. De Gentile, F. Legros). Personal Protection against biting insects and ticks. Parasite 2011; 18: 93-111

# En résumé...

- **Pendant le voyage:** La PPAV doit aussi prendre en compte le risque d'arbovirose et les nuisances liées aux piqûres d'insectes
- **Au retour:**
  - LMCA: efficacité de l'ivermectine; dg différentiel
  - LCL: indication Tt orientés par l'espèce et la sévérité, Tt local, absence de Tt,
  - Exanthème fébrile: dengue, chik (et Zika?)
- **Pb santé Publique :** importation arbovirale (*A.albopictus*)

A close-up photograph of a mosquito on human skin. The mosquito is positioned horizontally, facing towards the left. Its body is dark with distinct white spots on its abdomen. It has long, thin legs and two long, thin antennae. Its mouthparts are inserted into the skin of a person's arm, which is visible at the bottom of the frame. The skin is a light orange color. In the top left corner, there is a light blue circular graphic containing the text.

**Merci  
pour  
votre  
attention**